Lupus trials recruiting in Maryland

All Lupus trials nationally

Cities in Maryland

Recruiting trials in Maryland

• A Study in Participants With Active Systemic Lupus Erythematosus With Inadequate Response to Glucocorticoids and ≥2 Immunosuppressants
  NCT07175285 · Phase: Not specified · Ages: 16 Years and older · Sex: All (male and female) · Maryland: Rockville
• A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus
  NCT06617325 · Phase: Phase 3 · Ages: 16 Years and older · Sex: All (male and female) · Maryland: Rockville
• A Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus Erythematosus
  NCT07430306 · Phase: Phase 3 · Ages: 18 Years to 70 Years · Sex: All (male and female) · Maryland: Silver Spring
• A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease
  NCT07085104 · Phase: Phase 1 · Ages: 18 Years to 74 Years · Sex: All (male and female) · Maryland: Baltimore
• A Study to Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLE
  NCT06897930 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 70 Years · Sex: All (male and female) · Maryland: Baltimore, Bethesda
• An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants
  NCT05835310 · Phase: Phase 3 · Ages: 5 Years to 17 Years · Sex: All (male and female) · Maryland: Bethesda
• Deciphering the Genetic Architecture of Autoimmune Diseases
  NCT06948110 · Phase: Not specified · Ages: 18 Years to 115 Years · Sex: All (male and female) · Maryland: Bethesda
• Double-blind Placebo Controlled Study to Evaluate the Effect of NAD+ Boosting With Nicotinamide Riboside on Immunometabolism and Immunity in Systemic Lupus Erythematosus
  NCT06032923 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 120 Years · Sex: Female · Maryland: Bethesda
• Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopic Dermatitis
  NCT07262983 · Phase: Phase 1 · Ages: 12 Years to 120 Years · Sex: All (male and female) · Maryland: Bethesda
• Gonadotropin-releasing Hormone Agonist (GnRHa) in Ovarian Preservation in SLE Subjects Receiving Cyclophosphamide as Determined by Questionnaires
  NCT05567198 · Phase: Not specified · Ages: 18 Years to 120 Years · Sex: Female · Maryland: Bethesda
• PRESERVE: LUPKYNIS in Combination With Belimumab, Obinutuzumab or Anifrolumab in Patients With Lupus Nephritis
  NCT07611214 · Phase: Phase 4 · Ages: 18 Years to 75 Years · Sex: All (male and female) · Maryland: Rockville
• Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).
  NCT06133972 · Phase: Phase 3 · Ages: 12 Years to 100 Years · Sex: All (male and female) · Maryland: Baltimore
• Predictors of Pregnancy Outcome in Systemic Lupus Erythematosus (SLE) and Antiphospholipid Syndrome (APS)
  NCT00198068 · Phase: Not specified · Ages: 18 Years to 45 Years · Sex: Female · Maryland: Baltimore
• Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V
  NCT05268289 · Phase: Phase 2 · Ages: 18 Years to 100 Years · Sex: All (male and female) · Maryland: Baltimore
• Study of Systemic Lupus Erythematosus
  NCT00001372 · Phase: Not specified · Ages: 3 Years to 120 Years · Sex: All (male and female) · Maryland: Bethesda
• Study to Assess Real-world Effectiveness of Belimumab for Treatment of Adults With LN
  NCT06527872 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · Maryland: Baltimore
• Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
  NCT03816345 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Maryland: Baltimore, Bethesda
• The Role of Anifrolumab in Improving Markers of Vascular Risk in Patients With Systemic Lupus Erythematosus (SLE) - IFN-CVD
  NCT05440422 · Phase: Phase 2 · Ages: 18 Years to 80 Years · Sex: All (male and female) · Maryland: Bethesda